Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Transient receptor potential vanilloid type 1 and pain development.

Palazzo E, Luongo L, de Novellis V, Rossi F, Marabese I, Maione S.

Curr Opin Pharmacol. 2012 Feb;12(1):9-17. doi: 10.1016/j.coph.2011.10.022. Epub 2011 Nov 20. Review.

PMID:
22104468
2.

Moving towards supraspinal TRPV1 receptors for chronic pain relief.

Palazzo E, Luongo L, de Novellis V, Berrino L, Rossi F, Maione S.

Mol Pain. 2010 Oct 11;6:66. doi: 10.1186/1744-8069-6-66. Review.

3.

Role of TRPV1 receptors in descending modulation of pain.

Palazzo E, Rossi F, Maione S.

Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S79-83. doi: 10.1016/j.mce.2008.01.013. Epub 2008 Feb 2. Review.

PMID:
18325659
4.

Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy.

Silva M, Martins D, Charrua A, Piscitelli F, Tavares I, Morgado C, Di Marzo V.

Neuropharmacology. 2016 Aug;107:49-57. doi: 10.1016/j.neuropharm.2016.03.007. Epub 2016 Mar 8.

PMID:
26965218
5.

Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways.

Starowicz K, Maione S, Cristino L, Palazzo E, Marabese I, Rossi F, de Novellis V, Di Marzo V.

J Neurosci. 2007 Dec 12;27(50):13739-49.

6.

Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors.

Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V.

J Pharmacol Exp Ther. 2006 Mar;316(3):969-82. Epub 2005 Nov 11.

7.

Functional interaction between TRPV1 and mu-opioid receptors in the descending antinociceptive pathway activates glutamate transmission and induces analgesia.

Maione S, Starowicz K, Cristino L, Guida F, Palazzo E, Luongo L, Rossi F, Marabese I, de Novellis V, Di Marzo V.

J Neurophysiol. 2009 May;101(5):2411-22. doi: 10.1152/jn.91225.2008. Epub 2009 Mar 18.

8.

Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.

García-Martínez C, Fernández-Carvajal A, Valenzuela B, Gomis A, Van Den Nest W, Ferroni S, Carreño C, Belmonte C, Ferrer-Montiel A.

J Pain. 2006 Oct;7(10):735-46.

PMID:
17018334
10.

Transient receptor potential vanilloid 1 as a therapeutic target in analgesia.

Szolcsányi J, Pintér E.

Expert Opin Ther Targets. 2013 Jun;17(6):641-57. doi: 10.1517/14728222.2013.772580. Epub 2013 Feb 20. Review.

PMID:
23421411
11.

Diabetic thermal hyperalgesia: role of TRPV1 and CB1 receptors of periaqueductal gray.

Mohammadi-Farani A, Sahebgharani M, Sepehrizadeh Z, Jaberi E, Ghazi-Khansari M.

Brain Res. 2010 Apr 30;1328:49-56. doi: 10.1016/j.brainres.2010.02.077. Epub 2010 Mar 6.

PMID:
20211611
12.

TRPV1 signaling: mechanistic understanding and therapeutic potential.

Xia R, Samad TA, Btesh J, Jiang LH, Kays I, Stjernborg L, Dekker N.

Curr Top Med Chem. 2011;11(17):2180-91. Review.

PMID:
21671876
13.

Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity.

de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, Marabese I, D'Agostino G, Calignano A, Rossi F, Di Marzo V, Maione S.

Eur J Pharmacol. 2012 Feb 15;676(1-3):41-50. doi: 10.1016/j.ejphar.2011.11.034. Epub 2011 Dec 3.

PMID:
22178921
14.

Multisteric TRPV1 nocisensor: a target for analgesics.

Szolcsányi J, Sándor Z.

Trends Pharmacol Sci. 2012 Dec;33(12):646-55. doi: 10.1016/j.tips.2012.09.002. Epub 2012 Oct 12. Review.

PMID:
23068431
15.

Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel.

Chen X, Sun W, Gianaris NG, Riley AM, Cummins TR, Fehrenbacher JC, Obukhov AG.

J Biol Chem. 2014 Apr 4;289(14):9600-10. doi: 10.1074/jbc.M113.536862. Epub 2014 Feb 25.

16.

TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.

Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee CH, Sullivan JP, Faltynek CR.

J Neurosci. 2006 Sep 13;26(37):9385-93.

17.

7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.

Nash MS, McIntyre P, Groarke A, Lilley E, Culshaw A, Hallett A, Panesar M, Fox A, Bevan S.

J Pharmacol Exp Ther. 2012 Aug;342(2):389-98. doi: 10.1124/jpet.112.191932. Epub 2012 May 7.

18.

Supraspinal Transient Receptor Potential Subfamily V Member 1 (TRPV1) in Pain and Psychiatric Disorders.

Madasu MK, Roche M, Finn DP.

Mod Trends Pharmacopsychiatry. 2015;30:80-93. doi: 10.1159/000435934. Epub 2015 Sep 18. Review.

PMID:
26436415
19.

Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.

Voight EA, Kort ME.

Expert Opin Ther Pat. 2010 Sep;20(9):1107-22. doi: 10.1517/13543776.2010.497756. Review.

PMID:
20586701
20.

The Role of Cannabinoid Receptors in the Descending Modulation of Pain.

Palazzo E, Luongo L, Novellis V, Rossi F, Maione S.

Pharmaceuticals (Basel). 2010 Aug 16;3(8):2661-2673. Review.

Supplemental Content

Support Center